Shire submits Connexyn for ADHD
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Shire submitted an NDA Aug. 24 for its attention deficit/hyperactivity disorder compound SPD503 (guanfacine) with the proposed trade name Connexyn. If approved, the drug would be the second non-stimulant product in its category. The company submitted another ADHD drug in July - SPD465 - designed to provide sustained release of medication for 16 hours. SPD465 has a May 21, 2007 standard review user fee date for treatment of adult ADHD; the agent has the same active ingredient as Shire's established Adderall brand (1Pharmaceutical Approvals Monthly August 2006, In Brief)...
You may also be interested in...
Vyvanse’s Long Shadow: Launch To Decide Fate Of Two Other Shire NDAs
Shire is keeping two pending NDAs for new attention deficit hyperactivity disorder treatments in a sort of limbo while it waits to see if the high expectations for the launch of its d-amphetamine prodrug Vyvanse are fulfilled
Shire submits SPD465 for adult ADHD
Shire's attention deficit/hyperactivity disorder agent SPD465 has an estimated May 21, 2007 user fee date following the firm's July 21 submission. The amphetamine compound is designed to provide sustained release of medication for 16 hours. SPD465 has the same active ingredient as the firm's Adderall XR (mixed amphetamine salts), which provides treatment for 12 hours...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.